MA46955A - Nouveaux composés en tant qu'agonistes récepteurs de glp1/glucagon/gip trigonal peptidique - Google Patents

Nouveaux composés en tant qu'agonistes récepteurs de glp1/glucagon/gip trigonal peptidique

Info

Publication number: MA46955A
Authority: MA; Morocco
Prior art keywords: peptidique; glp1; trigonal; gip; glucagon
Prior art date: 2016-12-02

Application number

MA046955A

Other languages

English (en)

Inventor

Martin Bossart

Andreas Evers

Torsten Haack

Dieter Kadereit

Katrin Lorenz

Martin Lorenz

Stefania Pfeiffer-Marek

Michael Wagner

Original Assignee

Sanofi Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-12-02

Filing date

2017-12-01

Publication date

2021-05-19

2017-12-01 Application filed by Sanofi Sa filed Critical Sanofi Sa

2021-05-19 Publication of MA46955A publication Critical patent/MA46955A/fr

Links

102000051325 Glucagon Human genes 0.000 title 1
108060003199 Glucagon Proteins 0.000 title 1
108091016366 Histone-lysine N-methyltransferase EHMT1 Proteins 0.000 title 1
102100040918 Pro-glucagon Human genes 0.000 title 1
150000001875 compounds Chemical class 0.000 title 1
MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 title 1
229960004666 glucagon Drugs 0.000 title 1
239000000018 receptor agonist Substances 0.000 title 1
229940044601 receptor agonist Drugs 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Endocrinology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Zoology (AREA)
Diabetes (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Toxicology (AREA)
Biochemistry (AREA)
Vascular Medicine (AREA)
Epidemiology (AREA)
Obesity (AREA)
Hematology (AREA)
Cardiology (AREA)
Immunology (AREA)
Emergency Medicine (AREA)
Heart & Thoracic Surgery (AREA)
Child & Adolescent Psychology (AREA)
Hospice & Palliative Care (AREA)
Urology & Nephrology (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

MA046955A 2016-12-02 2017-12-01 Nouveaux composés en tant qu'agonistes récepteurs de glp1/glucagon/gip trigonal peptidique MA46955A (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP16306604		2016-12-02

Publications (1)

Publication Number	Publication Date
MA46955A true MA46955A (fr)	2021-05-19

Family

ID=57542935

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA046955A MA46955A (fr)	2016-12-02	2017-12-01	Nouveaux composés en tant qu'agonistes récepteurs de glp1/glucagon/gip trigonal peptidique

Country Status (23)

Country	Link
US (1)	US10538567B2 (fr)
EP (1)	EP3548508B1 (fr)
JP (1)	JP7100033B2 (fr)
KR (1)	KR102576872B1 (fr)
CN (1)	CN110023329B (fr)
AR (1)	AR110300A1 (fr)
AU (1)	AU2017367173B2 (fr)
BR (1)	BR112019011228A2 (fr)
CA (1)	CA3045377A1 (fr)
CL (1)	CL2019001465A1 (fr)
CO (1)	CO2019006917A2 (fr)
CR (1)	CR20190313A (fr)
DO (1)	DOP2019000068A (fr)
EA (1)	EA201991345A1 (fr)
EC (1)	ECSP19046893A (fr)
IL (1)	IL266984A (fr)
MA (1)	MA46955A (fr)
MX (1)	MX2019006429A (fr)
PE (1)	PE20191143A1 (fr)
PH (1)	PH12019501216A1 (fr)
TW (1)	TW201833132A (fr)
UY (1)	UY37506A (fr)
WO (1)	WO2018100134A1 (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AR110301A1 (es)	2016-12-02	2019-03-13	Sanofi Sa	Compuestos como agonistas peptídicos de receptores de glp1 / glucagón / gip
AR110300A1 (es)	2016-12-02	2019-03-13	Sanofi Sa	Compuestos como agonistas peptídicos trigonales de los receptores de glp1 / glucagón / gip
KR102793451B1 (ko)	2018-04-10	2025-04-11	사노피-아벤티스 도이칠란트 게엠베하	고체상으로부터 고체상-결합된 펩타이드를 절단하는 방법
BR112020020647A2 (pt)	2018-04-10	2021-02-23	Sanofi-Aventis Deutschland Gmbh	síntese de lixisenatida com capeamento
TW202015735A (zh)	2018-05-30	2020-05-01	法商賽諾菲公司	包含ｇｌｐ－１／升糖素／ｇｉｐ三重受體促效劑、連接子及透明質酸之接合物
KR20200078413A (ko) *	2018-12-21	2020-07-01	한미약품 주식회사	글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체 및 인슐린을 포함하는 약학 조성물
CA3138715A1 (fr)	2019-06-14	2020-12-17	Zealand Pharma A/S	Composition pharmaceutique parenterale d'agoniste de glp1/2 double
CN114786706A (zh) *	2019-10-04	2022-07-22	韩美药品株式会社	胰高血糖素、包含glp-1受体和gip受体双重激动剂的组合物、及其治疗用途
PE20221168A1 (es)	2019-11-11	2022-07-25	Boehringer Ingelheim Int	Agonistas del receptor npy2
TW202228762A (zh) *	2020-01-30	2022-08-01	美商美國禮來大藥廠	提派肽(tirzepatide)之治療用途
UA130066C2 (uk)	2020-08-07	2025-10-29	Бьорінгер Інгельхайм Інтернаціональ Гмбх	Розчинні агоністи рецепторів npy2
EP4197550A4 (fr) *	2020-08-14	2025-10-08	Hanmi Pharmaceutical Co Ltd	Composition pharmaceutique à effet hypotenseur comprenant un activateur triple présentant une activité pour tous les récepteurs du glucagon, de la glp-1, et de la gip
CN114349828B (zh) *	2020-11-27	2023-12-08	江苏师范大学	Glp-1/胰高血糖素受体双重激动剂及其应用
JP7751641B2 (ja) *	2020-12-16	2025-10-08	ジーランドファーマエー／エス	Ｇｌｐ－１／ｇｌｐ－２デュアルアゴニストの医薬組成物
EP4262745B1 (fr) *	2020-12-16	2025-01-29	Zealand Pharma A/S	Composition pharmaceutique d'agonistes doubles de glp-1/glp-2
AU2022298632A1 (en) *	2021-06-25	2023-12-14	Eli Lilly And Company	Methods for treating obstructive sleep apnea
KR20230004135A (ko) *	2021-06-30	2023-01-06	한미약품 주식회사	글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체를 포함하는 조합물의 치료학적 용도
AU2023276018A1 (en) *	2022-05-27	2024-11-21	D&D Pharmatech Inc.	Peptide compositions and methods of use threof
EP4596574A1 (fr) *	2022-09-28	2025-08-06	Sunshine Lake Pharma Co., Ltd.	Agoniste du récepteur triple glp-1/gcg/gip et son utilisation
AU2023408167B2 (en) *	2022-12-23	2025-09-04	Hanmi Pharm. Co., Ltd.	Novel triple GLP-1/GIP/glucagon receptor agonist and a pharmaceutical composition for preventing or treating obesity comprising the same
WO2025049610A1 (fr) *	2023-08-28	2025-03-06	Shattuck Labs, Inc.	Peptides multi-actions
CN117586374B (zh) *	2023-10-07	2024-11-29	深圳湾实验室	Glp-1r/gipr/gcgr三重激动剂类似物及其用途
CN119241684B (zh) *	2024-11-22	2025-02-25	徐州医科大学	一种肠促胰岛素类似物及其用途

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PL377591A1 (pl)	2002-10-02	2006-02-06	Zealand Pharma A/S	Stabilizowane związki eksendyny-4
US20080019911A1 (en) *	2005-04-20	2008-01-24	Aimin Xu	Method for decreasing blood glucose and improving glucose tolerance using angiopoietin-like protein 4
DK1891105T3 (da)	2005-06-13	2012-07-16	Imp Innovations Ltd	Hidtil ukendte forbindelser og deres påvirkninger på spiseadfærd
BRPI0915282A2 (pt)	2008-06-17	2017-02-07	Univ Indiana Res & Tech Corp	agonistas mistos baseados no gip para o tratamento de distúrbios metabólicos e obesidade
US9150632B2 (en)	2009-06-16	2015-10-06	Indiana University Research And Technology Corporation	GIP receptor-active glucagon compounds
US20120148586A1 (en)	2009-08-27	2012-06-14	Joyce Ching Tsu Chou	Glucagon-like protein-1 receptor (glp-1r) agonists for treating autoimmune disorders
AU2011202239C1 (en)	2010-05-19	2017-03-16	Sanofi	Long-acting formulations of insulins
CA2821766A1 (fr)	2010-12-22	2012-06-28	Indiana University Research And Technology Corporation	Analogues du glucagon presentant une activite de recepteur de gip
JP6300239B2 (ja)	2012-06-21	2018-03-28	インディアナユニバーシティーリサーチアンドテクノロジーコーポレーションＩｎｄｉａｎａＵｎｉｖｅｒｓｉｔｙＲｅｓｅａｒｃｈＡｎｄＴｅｃｈｎｏｌｏｇｙＣｏｒｐｏｒａｔｉｏｎ	Ｇｉｐ受容体活性を示すグルカゴンアナローグ
RU2015101697A (ru)	2012-06-21	2016-08-10	Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн	Аналоги глюкагона, обладающие активностью рецептора gip
AR092873A1 (es)	2012-09-26	2015-05-06	Cadila Healthcare Ltd	Peptidos como agonistas triples de los receptores de gip, glp-1 y glugagon
UA116217C2 (uk)	2012-10-09	2018-02-26	Санофі	Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
SG10201705097PA (en)	2012-12-21	2017-07-28	Sanofi Sa	Functionalized exendin-4 derivatives
EA035688B1 (ru)	2013-11-06	2020-07-27	Зилэнд Фарма А/С	Соединения, которые представляют собой тройные агонисты глюкагона, glp-1 и gip
EP3080151A1 (fr)	2013-12-13	2016-10-19	Sanofi	Analogues peptidiques de l'exendine 4
WO2015086731A1 (fr)	2013-12-13	2015-06-18	Sanofi	Analogues peptidiques de l'exendine-4 en tant qu'agonistes mixtes des récepteurs glp-1/glucagon
EP3080149A1 (fr)	2013-12-13	2016-10-19	Sanofi	Agonistes mixtes des récepteurs du glp-1/glucagon
TW201625670A (zh) *	2014-04-07	2016-07-16	賽諾菲公司	衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625669A (zh)	2014-04-07	2016-07-16	賽諾菲公司	衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625668A (zh)	2014-04-07	2016-07-16	賽諾菲公司	作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
WO2016198624A1 (fr)	2015-06-12	2016-12-15	Sanofi	Dérivés d'exendine 4 utilisés en tant qu'agonistes trigonaux des récepteurs du glp-1/glucagon/gip
AR110300A1 (es)	2016-12-02	2019-03-13	Sanofi Sa	Compuestos como agonistas peptídicos trigonales de los receptores de glp1 / glucagón / gip
AR110301A1 (es)	2016-12-02	2019-03-13	Sanofi Sa	Compuestos como agonistas peptídicos de receptores de glp1 / glucagón / gip

2017
- 2017-11-30 AR ARP170103362A patent/AR110300A1/es unknown
- 2017-11-30 TW TW106141759A patent/TW201833132A/zh unknown
- 2017-12-01 MA MA046955A patent/MA46955A/fr unknown
- 2017-12-01 MX MX2019006429A patent/MX2019006429A/es unknown
- 2017-12-01 CN CN201780074707.9A patent/CN110023329B/zh active Active
- 2017-12-01 EP EP17821804.6A patent/EP3548508B1/fr active Active
- 2017-12-01 JP JP2019529535A patent/JP7100033B2/ja active Active
- 2017-12-01 WO PCT/EP2017/081125 patent/WO2018100134A1/fr not_active Ceased
- 2017-12-01 UY UY0001037506A patent/UY37506A/es unknown
- 2017-12-01 AU AU2017367173A patent/AU2017367173B2/en active Active
- 2017-12-01 US US15/829,680 patent/US10538567B2/en active Active
- 2017-12-01 CR CR20190313A patent/CR20190313A/es unknown
- 2017-12-01 EA EA201991345A patent/EA201991345A1/ru unknown
- 2017-12-01 BR BR112019011228A patent/BR112019011228A2/pt not_active Application Discontinuation
- 2017-12-01 PE PE2019000905A patent/PE20191143A1/es unknown
- 2017-12-01 CA CA3045377A patent/CA3045377A1/fr not_active Abandoned
- 2017-12-01 KR KR1020197018943A patent/KR102576872B1/ko active Active
2019
- 2019-03-19 DO DO2019000068A patent/DOP2019000068A/es unknown
- 2019-05-29 IL IL266984A patent/IL266984A/en unknown
- 2019-05-30 CL CL2019001465A patent/CL2019001465A1/es unknown
- 2019-05-31 PH PH12019501216A patent/PH12019501216A1/en unknown
- 2019-06-27 CO CONC2019/0006917A patent/CO2019006917A2/es unknown
- 2019-07-01 EC ECSENADI201946893A patent/ECSP19046893A/es unknown

Also Published As

Publication number	Publication date
CO2019006917A2 (es)	2019-07-10
EP3548508A1 (fr)	2019-10-09
EP3548508B1 (fr)	2021-10-27
WO2018100134A1 (fr)	2018-06-07
ECSP19046893A (es)	2019-07-31
CR20190313A (es)	2019-09-11
DOP2019000068A (es)	2019-05-31
EA201991345A1 (ru)	2019-11-29
BR112019011228A2 (pt)	2019-10-15
KR20190085141A (ko)	2019-07-17
AR110300A1 (es)	2019-03-13
CN110023329A (zh)	2019-07-16
UY37506A (es)	2018-06-29
KR102576872B1 (ko)	2023-09-12
PH12019501216A1 (en)	2019-08-19
AU2017367173A1 (en)	2019-07-18
CL2019001465A1 (es)	2019-10-18
CA3045377A1 (fr)	2018-06-07
MX2019006429A (es)	2019-08-21
US20180155406A1 (en)	2018-06-07
IL266984A (en)	2019-07-31
PE20191143A1 (es)	2019-09-02
JP7100033B2 (ja)	2022-07-12
TW201833132A (zh)	2018-09-16
AU2017367173B2 (en)	2022-03-24
US10538567B2 (en)	2020-01-21
JP2019536796A (ja)	2019-12-19
CN110023329B (zh)	2024-05-03

Publication	Publication Date	Title
MA46955A (fr)	2021-05-19	Nouveaux composés en tant qu'agonistes récepteurs de glp1/glucagon/gip trigonal peptidique
EP3621624A4 (fr)	2021-03-24	Composés dinucléotidiques cycliques en tant qu'agonistes sting
HUE069365T2 (hu)	2025-03-28	Kondenzált gyûrûs vegyületek
MA43169A (fr)	2018-09-12	Composés hétérocycliques utilisés en tant qu'inhibiteurs de pi3k-gamma
EP3344644A4 (fr)	2019-02-27	Composés di-nucléotidiques cycliques en tant qu'agonistes de sting
MA51878A (fr)	2020-12-30	Composés d'aminothiazole en tant qu'inhibiteurs de c-kit
MA53150A (fr)	2021-05-26	Composés de benzimidazole en tant qu'inhibiteurs de c-kit
SI3523287T1 (sl)	2021-11-30	Benzo(b)tiofenske spojine kot agonisti STING
MA55194A (fr)	2022-05-04	Composés hétérocycliques en tant qu'immunomodulateurs
MA52189A (fr)	2021-02-17	Benzothiophènes et composés associés utilisés en tant qu'agonistes de sting
MA42990A (fr)	2021-03-31	Composés utiles en tant qu'immunomodulateurs
MA45377A (fr)	2019-04-24	Composés hétérocycliques en tant qu'agents antibacteriens
MA47013A (fr)	2018-08-29	Composés benzolactames utilisés en tant qu'inhibiteurs de protéine kinase
MA41551A (fr)	2017-12-26	Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
MA46091A (fr)	2019-07-10	Composés biaryles utiles en tant qu'immunomodulateurs
MA40587A (fr)	2017-06-28	Composés d'aminopyrimidinyle en tant qu'inhibiteurs de jak
DK3762380T3 (da)	2022-01-17	Phenylpyrrolidinon-formylpeptid-2-receptoragonister
MA51438A (fr)	2021-04-14	Composés hétérocycliques utilisés en tant qu'inhibiteurs de lsd1
MA52754A (fr)	2021-04-14	Composés hétérocycliques tricycliques en tant qu'activateurs de sting
MA42919A (fr)	2018-08-01	Composés bicycliques utilisés en tant qu'inhibiteurs d'atx
EP3344295A4 (fr)	2019-05-01	Récepteurs d'antigène chimère tn anti-sialyle
MA42918A (fr)	2018-08-01	Composés bicycliques utilisés en tant qu'inhibiteurs d'atx
HRP20190388T1 (hr)	2019-04-19	Eksendin-4 derivati kao peptidni dvostruki agonisti receptora glp-1 / glukagona
EP3386981A4 (fr)	2019-06-19	Hétérocycles utiles en tant qu'agents anticancereux
MA45375A (fr)	2019-04-24	Composés hétérocycliques utilisés en tant qu'agents antibacteriens